KURA

KURA EBITDA Growth

-52.35%TTM

Period ending:

KURA TTM EBITDA YoY %%
KURA TTM EBITDA YoY %15971.13%-148519.18%
2011-03-312026-06-30

Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.

KURA ebitda growth history

Year-over-year EBITDA growth rate. The available trailing twelve months (ttm) series contains 62 observations from Mar 31, 2011 to Jun 30, 2026.

Kura Oncology Inc EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
-52.3457%
-64.2448%
-63.4131%
-9.3862%
-7.7782%
-7.4396%
-12.8234%
-38.619%
-29.8552%
-21.7174%
-11.4058%
-4.4408%
-4.0846%
-3.643%
-4.1376%
-9.7098%
-17.2117%
-30.945%
-45.7396%
-52.2568%
-54.2531%
-47.8268%
-42.0455%
-32.8246%
-23.8366%
-15.1183%
-5.1886%
-12.3571%
-22.4029%
-41.8527%
-72.2882%
-73.4167%
-68.0906%
-48.4718%
-24.674%
-13.863%
-6.3608%
-6.8074%
-16.104%
-60.8535%
-155.4543%
-457.4152%
-132,600.7624%
-99,575.4656%
-49,079.0292%
-21,490.9158%
19.5694%
29.2181%
11.5938%
8.9985%
4.6886%
-26.8911%
-24.0963%
3.3737%
19.2865%
50.5257%
52.7155%
40.6162%
29.1994%
33.5409%
26.3867%
47.7791%

Compare ebitda growth

All KURA financial metrics · KURA stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.